Andrew McConaghie
Senior Writer
Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest From Andrew McConaghie
AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
Allogene Frustrated By FDA’s Delayed CAR-T Trial Review
Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”
Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.
Pharma Past Propels Julie Brown To GSK’s CFO Position
GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.
Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS
After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?